A clinical observation of hepatic vein pressure gradient and flow rate after Octreotide treatment of bleeding esophageal varices

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2015, Vol. 20 ›› Issue (4): 441-444.

Previous Articles Next Articles

A clinical observation of hepatic vein pressure gradient and flow rate after Octreotide treatment of bleeding esophageal varices

WU Chun-song¹, ZHANG Ling², ZHOU Wei², FENG Yi-zheng³, ZHU Peng-wu¹

¹ Department of Gastroenterology, the First Poeple's Hospital of Linhai, Linhai 317000, Zhejiang, China;
² Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
³ Radiology Department, the First Poeple's Hospital of Linhai, Linhai 317000, Zhejiang, China

Received:2014-03-27 Revised:2014-06-23 Published:2015-05-07

Abstract

Abstract: AIM: To observe the change of hepatic vein pressure gradient (HVPG) after Octreotide treatment of bleeding esophageal varice (BEV).METHODS: BEV patients were randomly assigned to low dose Octreotide group (group A, n=18); high dose octreotide group (group B, n=18) and control group (n=18). The three groups were treated by the same basic method (abrosia, transfusion, blood transfusion and symptomatic treatment). Patients in group A and B were administered octreotide at a rate of 25 μg/h and 50 μg/h respectively. HVPG and other clinical parameters of patients in all the groups were observed and comparatively analyzed.RESULTS: The HVPG of patients in group A and B were significantly different before and after 24 h and 72 h post-octreotide treatment compared with that of group C (P=0.00,P=0.00). There was a significant difference between group A and group B after 24 h octreotide treatment also(P=0.00), but There was no significant difference after 72 h (P=0.14).CONCLUSION: Octreotide is effective in the treatment of BEV by reducing HVPG and its effect is significantly different from omeprazole monotherapy.

Key words: Octreotide, esophageal varices bleeding, hepatic vein pressure gradient, flow rate

CLC Number:

R571

WU Chun-song, ZHANG Ling, ZHOU Wei, FENG Yi-zheng, ZHU Peng-wu. A clinical observation of hepatic vein pressure gradient and flow rate after Octreotide treatment of bleeding esophageal varices[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 441-444.

References

[1] 冷希圣,王维民,周光文.肝硬化门静脉高压症消化道出血治疗共识[J].外科理论与实践,2009,14(1): 79-81.
[2] Helmy A,Hayes PC. Review article: current endoscopic therapeutic optious in the management of variceal bleeding[J]. Aliment Pharmacol Ther ,2001, 15(5): 575-594.
[3] Boyer TD. Pharmacologic treatment of portal hypertension: Past, present, and future[J]. Hepatology, 2001, 34 (4 Pt 1): 834-839.
[4] Zhou Y, Qiao L, Wu J, et al. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study[J]. J Gastroenterol Hepatol ,2002, 17(9): 973-979.
[5] de Franchis R. Somatostatin, omatostain analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices[J]. Dig liver Dis, 2004, 36 Suppl 1:S93-100.
[6] Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension[J]. Hepatology, 2012, 35(6): 1305-1312.
[7] D'Amico G, Politi F, Morabito A, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial[J]. Hepatology, 1998, 28(5):1206-1214.
[8] Dagher L, Burroughs A. Variceal bleeding and portal hypertensive gastropathy[J]. Eur J Gsatroenterol Hepatol ,2001,13(1): 8-88.
[9] Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis[J]. Hepatology, 2002, 35(3): 609-615.
[10]Lata J, Hulek P, Vanasek T. Management of acute variceal bleeding[J]. Dig Dis, 2003, 21(1): 6-15.
[11] Seewald S, Mendoza G, Seitz V, et al. Variceal bleeding and portal hypertension: has there been any progress in the last 12 months? Endoscopy, 2003, 35(2): 136-144.
[12] Lee TH. Recent adcances in diagnosis of portal hypertension[J]. Korean J Gsatroentrol, 2010, 56(3) : 135-143.
[13] 王华富,丁汀,尚振球,等.奥曲肽对肝硬化食管胃底静脉曲张破裂出血维持治疗的Meta-分析[J].中国临床药理学与治疗学,2012,17(7): 768-772.
[14] Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis[J]. Gastroenterology, 2001, 120(4): 946-954.
[15] 仇日火,郑玉风,季秀英,等.肝硬化门脉高压及其相关因素的临床研究[J].中华消化杂志,1992, 12:220-222.

A clinical observation of hepatic vein pressure gradient and flow rate after Octreotide treatment of bleeding esophageal varices

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	WANG Hua-fu,DING Ting, SHANG Zhen-qiu, GUI Zhi-hong, LIN Hui-ping, SUN Hui-lin. Effect of octreotide on maintaining treatment of esophageal and gastric fundus varices hemorrhage: A meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 768-772.
[2]	LI Chang-Zheng, WANG Zhi-Qiang, FANG Yi. Inhibition of octreotide on the proliferation of the in vitro cultured liver cancer cell SMMC-7721 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 919-921.